Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

111.00DKK
7:44am EDT
Change (% chg)

kr.-2.50 (-2.20%)
Prev Close
kr.113.50
Open
kr.113.50
Day's High
kr.113.50
Day's Low
kr.110.00
Volume
106,213
Avg. Vol
140,683
52-wk High
kr.170.00
52-wk Low
kr.90.50

ZELA.CO

Chart for ZELA.CO

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 1.16
Market Cap(Mil.): kr.2,784.63
Shares Outstanding(Mil.): 24.53
Dividend: --
Yield (%): --

Financials

  ZELA.CO Industry Sector
P/E (TTM): -- 37.83 36.47
EPS (TTM): -6.08 -- --
ROI: -26.41 -0.04 14.19
ROE: -67.66 -2.02 15.16

BRIEF-Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi

* Zealand announces new timelines for a U.S. FDA decision on iglarlixi, the fixed-ratio combination of lixisenatide (adlyxintm) and lantus(r), for the treatment of type 2 diabetes

Aug 19 2016

BRIEF-Zealand Pharma: supportive results from Phase II trial of dasiglucagon

* Announced on Thursday supportive results from a Phase II trial with a single-dose version of dasiglucagon as rescue treatment of severe hypoglycemia

Aug 12 2016

BRIEF-Zealand Pharma: royalty revenue of DKK 6.4 mln in Q2 on sales of Lyxumia

* Lixisenatide as adlyxin to treat type 2 diabetes commercial launch by Sanofi in U.S. is expected later in H2

Jul 29 2016

BRIEF-Zealand Pharma: FDA approves lixisenatide in the U.S.

* FDA approves lixisenatide as Adlyxin for the treatment of adults with type 2 diabetes in the U.S.

Jul 28 2016

BRIEF-Zealand Pharma: Positive results from pivotal Phase III clinical trials with iGlarLixi

* Positive results from pivotal Phase III clinical trials with iGlarLixi

Jun 13 2016

BRIEF-Zealand Pharma and Beta Bionics to collaborate

* The company and Beta Bionics to collaborate on development of first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes

Jun 10 2016

BRIEF-Sunstone's 13 pct stake in Zealand Pharma to be distributed to institutional investors

* Says proposed voluntary liquidation of certain Sunstone managed funds during Q3 will lead to distribution of 13 pct of Zealand's share capital to broad group of institutional investors

Jun 02 2016

BRIEF-Zealand Pharma Q1 net loss widening to DKK 72.8 million

* Q1 revenue 6.5 million Danish crowns versus 6.3 million crowns year ago

May 18 2016

BRIEF-Zealand Pharma gives results of elsiglutide Phase IIb trial

* Announced on Wednesday results of Helsinn's Phase IIb trial with elsiglutide for prevention of chemotherapy-induced diarrhea in colorectal cancer patients

May 05 2016

BRIEF-Zealand Pharma Lyxumia royalty revenue for Q1 2016 up 3 pct

* Zealand reports Lyxumia royalty revenue for Q1 2016 andmsubmission by Sanofi of the fixed-ratio combination of insulin glargine (Lantus) and lixisenatide for European registration

Apr 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : GlobalData
$300.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.